Most Volatile Drug Stocks: Zogenix (NASDAQ:ZGNX), Provectus Biopharmaceuticals (NYSEMKT:PVCT), ITI (NASDAQ:ITCI), Echo Therapeutics (NASDAQ:ECTE), Pfizer (NYSE:PFE)

Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, announced that Ann Rhoads, Chief Financial Officer, will be presenting at The second conference is The JMP Securities Healthcare Conference on June 24, 2014 in New York, NY.  Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is 7.10%. On last trading day company shares ended up $1.81. Analysts mean target price for the company is $4.48. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is -19.95%.

Law Offices of Howard G. Smith announced on 17 June that a class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee on behalf of all purchasers of the securities of Provectus Biopharmaceuticals Inc. (NYSE:PVCT) between December 17 2013 and May 22 2014 inclusive. Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) shares fell -3.54% in last trading session and ended the day on $1.09. PVCT return on assets is -225.20%.Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) quarterly performance is 23.47%.

ITI Inc. (NASDAQ:ITCI) VP Lawrence P. Wennogle sold 6,000 shares of ITI stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $15.00, for a total value of $90,000.00. Following the completion of the transaction, the vice president now directly owns 106,500 shares of the company’s stock, valued at approximately $1,597,500. ITI Inc. (NASDAQ:ITCI) shares moved up 1.31% in last trading session and was closed at $18.52, while trading in range of $17.12 – $18.80. ITI Inc. (NASDAQ:ITCI) year to date (YTD) performance is 3.24%.

Echo Therapeutics, Inc. (NASDAQ:ECTE) a medical device company developing its Symphony((R)) CGM System as a non-invasive, wireless continuous glucose monitoring system, announced that, based on preliminary results provided by Echo’s proxy solicitor, stockholders have elected Shepard M. Goldberg as a new member of the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on Thursday, June 19, 2014. Echo Therapeutics Inc. (NASDAQ:ECTE) ended the last trading day at $2.11. Company weekly volatility is calculated as 7.09% and price to cash ratio as 3.56.Echo Therapeutics Inc. (NASDAQ:ECTE) showed a negative weekly performance of -4.52%.

Pfizer Inc. (NYSE:PFE) entered into an agreement with a France-based biopharmaceutical company, Cellectis to develop chimeric antigen receptor T-cell (CAR-T) immunotherapies directed at select targets. With this deal, Pfizer intends to develop immuno-oncology therapies. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 0.48%. On last trading day company shares ended up $29.59. Analysts mean target price for the company is $34.55. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -0.74%.